Aralez Pharmaceuticals Inc. (ARLZ) Shares Bought by Isthmus Partners LLC
Isthmus Partners LLC raised its position in shares of Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) by 0.8% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 154,387 shares of the company’s stock after acquiring an additional 1,285 shares during the period. Isthmus Partners LLC owned approximately 0.23% of Aralez Pharmaceuticals worth $208,000 at the end of the most recent quarter.
Several other large investors have also recently modified their holdings of ARLZ. Franklin Street Advisors Inc. NC boosted its stake in shares of Aralez Pharmaceuticals by 67.5% in the second quarter. Franklin Street Advisors Inc. NC now owns 99,229 shares of the company’s stock valued at $134,000 after buying an additional 40,000 shares during the period. Salzhauer Michael boosted its stake in shares of Aralez Pharmaceuticals by 4.5% in the second quarter. Salzhauer Michael now owns 106,293 shares of the company’s stock valued at $144,000 after buying an additional 4,600 shares during the period. FNY Managed Accounts LLC boosted its stake in shares of Aralez Pharmaceuticals by 4.2% in the first quarter. FNY Managed Accounts LLC now owns 77,119 shares of the company’s stock valued at $165,000 after buying an additional 3,136 shares during the period. Goldman Sachs Group Inc. boosted its stake in shares of Aralez Pharmaceuticals by 0.3% in the first quarter. Goldman Sachs Group Inc. now owns 121,494 shares of the company’s stock valued at $260,000 after buying an additional 354 shares during the period. Finally, KCG Holdings Inc. bought a new stake in shares of Aralez Pharmaceuticals in the first quarter valued at approximately $310,000. Institutional investors own 23.79% of the company’s stock.
Shares of Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) traded down 0.5704% during midday trading on Wednesday, hitting $1.4119. The company had a trading volume of 19,191 shares. The company’s market capitalization is $94.38 million. Aralez Pharmaceuticals Inc. has a 12-month low of $0.95 and a 12-month high of $5.90. The company’s 50-day moving average price is $1.19 and its 200 day moving average price is $1.54.
Aralez Pharmaceuticals (NASDAQ:ARLZ) last released its quarterly earnings data on Wednesday, August 9th. The company reported ($0.42) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.41) by ($0.01). The business had revenue of $27.62 million during the quarter, compared to the consensus estimate of $21.37 million. Aralez Pharmaceuticals had a negative return on equity of 90.17% and a negative net margin of 122.35%. The firm’s quarterly revenue was up 119.6% on a year-over-year basis. During the same period last year, the business posted ($0.27) earnings per share. Equities research analysts predict that Aralez Pharmaceuticals Inc. will post ($1.62) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Aralez Pharmaceuticals Inc. (ARLZ) Shares Bought by Isthmus Partners LLC” was first reported by Daily Political and is the sole property of of Daily Political. If you are reading this article on another site, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/09/20/aralez-pharmaceuticals-inc-arlz-shares-bought-by-isthmus-partners-llc.html.
ARLZ has been the subject of several recent research reports. Chardan Capital cut their price target on Aralez Pharmaceuticals from $5.50 to $4.00 and set a “buy” rating for the company in a research note on Thursday, August 10th. ValuEngine cut Aralez Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd.
About Aralez Pharmaceuticals
Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.
Want to see what other hedge funds are holding ARLZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ).
Receive News & Ratings for Aralez Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.